Corporate Banner
Satellite Banner
Technology Networks Header
Monday, September 22, 2014
Technology Networks
 
Register | Sign in
Home Page
  Permissions

Permission to use, copy and distribute documents presented on this World Wide Web site and related graphics is not granted without prior written permission of Technology Networks Ltd

To obtain this permission contact:
Technology Networks Ltd
Unit 6, Woodview
Bull Lane
Acton
Sudbury
CO10 0FD, U.K.

In cases where permission is granted, it is done so under the provision that the above copyright notice and this permission notice appear in all copies. All other rights are reserved.

The information and data included in the TechnologyNetworks.com WWW site, and all its affiliated websites and associated email newsletters, have been compiled from a variety of sources, and are subject to change without notice. Technology Networks Ltd. makes no warranties or representations whatsoever regarding the quality, content, completeness, or adequacy of this information and data.

Technology Networks Ltd. specifically disclaims all warranties with respect to this WWW site, email newsletters or your use thereof, express, implied, or otherwise, including without limitation, all warranties of merchantability and fitness for a particular purpose. Technology Networks Ltd shall not be liable for any special, incidental, or consequential damages, including, without limitation, lost revenues, lost profits, or loss of prospective economic advantage, resulting from the use or misuse of this site, or the information therein.

Scientific News
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Leukemia Subtype Becomes More Common With Age
Genomic Analysis of 1,725 patients reveals the prevalence of Ph-like ALL increases with age.
Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes
UC San Diego is initial site for first-in-human testing of implanted cell therapy.
NIH to Launch Human Safety Study of Ebola Vaccine Candidate
Trial is First in Series of Accelerated Safety Studies of Ebola Vaccines.
NIH Announces the Launch of 3 Integrated Precision Medicine Trials
ALCHEMIST is for patients with certain types of early-stage lung cancer.
Monthly Blood Transfusions Reduce Sickle Cell Anemia-related Brain Injury in Children
NIH-funded study provides hope for children with disease-related brain damage.
Experimental Chikungunya Vaccine Induces Robust Antibody Response
Vaccine developed by NIH scientists performs well in early clinical trial.
Clinical Trial Evaluates Safety of Stem Cell Transplantation in Spine
Phase I clinical trial is recruiting eight patients for the 5-year study.
First Gene Therapy Trial Launched for Heart Patients with Mechanical Pumps
Patient received new gene therapy at Harefield Hospital, London.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv